Real-world evidence (RWE) generates largest study population in patients with aNSCLC

• Patients EPRs were utilised to generate RWE on treatment patterns and clinical outcomes for patients with aNSCLC in the UK
• 1003 patients who started a first-line treatment for aNSCLC were included from nine UK hospitals
• The evidence highlighted the need for improved treatment options for tumours lacking targetable mutations

Click here to read more

About SVMPharma

SVMPharma is an innovative strategic consultancy, specialising in Real-World Evidence (RWE) for the pharmaceutical industry. SVMPharma generates RWE within UK and Europe through bespoke online Real-World Treatment Evaluators, leading to successful health technology appraisal (HTA) submissions. Clinical trial programmes do not reflect real-world clinical practice and outcomes, RWE supplements and enhances clinical datasets. SVMPharma’s specialist teams focus on delivering the outcomes that matter to your brand.

For more information, please visit www.svmpharma.com and contact us at enquiry@svmpharma.com

ref: NOV2020BS001